PORTLAND, Oregon, December 2, 2014 /PRNewswire/ --

Research Beam adds a report titled "Breast Cancer Therapeutics in Asia-Pacific Markets to 2020 - Novel HER-2 Positive Therapies Provide Diversified Treatment Options" that provides detailed information of the Breast Cancer Therapeutics in Asia-Pacific Markets. The report is an excellent piece of study for investors who are looking towards the market.

GBI Research, the leading business intelligence provider, has released its latest research: "Breast Cancer Therapeutics in Asia-Pacific Markets to 2020 - Novel HER-2 Positive Therapies Provide Diversified Treatment Options", which provides in-depth analysis of breast cancer market within the Asia-Pacific (APAC) covering the four countries of Australia, China, India and Japan. The report provides an estimation of market size for 2013, along with market forecast until 2020. It also covers disease epidemiology, treatment algorithms, treatment patterns, in-depth analysis of the pipeline, and deal analysis.

See Complete Report with TOC at http://www.researchbeam.com/breast-cancer-therapeutics-in-asia-pacific-to-2020-novel-her-2-positive-therapies-provide-diversified-treatment-options-market

The breast cancer therapeutics market in the four Asia-Pacific (APAC) countries of India, Australia, China and Japan was worth $1.5 billion in 2013 and is expected to grow at a Compound Annual Growth Rate (CAGR) of 7.6% to $2.5 billion by 2020. Japan had the largest market in 2013 with a value of $872m, or a share of 58%, followed by China with $320m or 21%, and Australia with $234m or 16%. India had the lowest market share and value at 5% and $81m, but is expected to witness the fastest growth over the forecast period with a CAGR of 13.8%, compared to Australia at 7.8% and China and Japan both at 7.7%.

Scope 

The report analyzes treatment usage patterns, market characterization, pipeline analysis and key licensing and co-development deals in the breast cancer therapeutics in the four APAC markets of Australia, China, India and Japan. The report includes -

• Disease overview, as well as treatment algorithms and treatment usage patterns
• Market size and forecast for the APAC breast cancer market from 2013 to 2020
• Major marketed products in the APAC region along with a heat map of product performance
• In-depth pipeline analysis for global pipeline in breast cancer drugs along with clinical trial failure rate analysis
• Key drivers and restraints that have had and are expected to have a significant impact upon the market
• Key licensing and co-development agreements that could have impact on growth trends

Reasons to buy 

The report will enhance your decision-making capability by allowing you to -

• Align your product portfolio to the markets with high growth potential
• Develop market entry and expansion strategies by identifying the potential regions and therapeutic segments poised for strong growth
• Devise a more effectively tailored country strategy through the understanding of key drivers and barriers in the breast cancer drugs market
• Develop key strategic initiatives based upon an understanding of key focus areas and leading companies
• Accelerate and strengthen your market position by identifying key companies for mergers, acquisitions and strategic partnerships

Request for Discount: http://www.researchbeam.com/breast-cancer-therapeutics-in-asia-pacific-to-2020-novel-her-2-positive-therapies-provide-diversified-treatment-options-market/purchase-enquiry

Table of Contents

1 Table of Contents 5
1.1 List of Tables 7
1.2 List of Figures 7

2 Breast Cancer Therapeutics in Asia-Pacific Markets to 2020 -Introduction 8
2.1 Breast Cancer 8
2.2 Symptoms 8
2.3 Epidemiology 9
2.4 Pathophysiology 10
2.5 Diagnosis 10
2.6 Prognosis and Disease Staging 11
2.6.1 Classification 12
2.7 Treatment Options 13
2.7.1 Surgery and Radiation Therapy 13
2.7.2 Chemotherapy 13
2.7.3 Hormonal Therapies 14
2.7.4 Targeted Therapies 14
2.7.5 Resistance to Pharmacological Therapies 15
2.7.6 Treatment Guidelines 15
2.7.7 Measuring the Effectiveness of Treatment 18

3 Breast Cancer Therapeutics in Asia-Pacific Markets to 2020 - Marketed Products 19
3.1 Key Marketed Products 19
3.1.1 Herceptin 19
3.1.2 Halaven 21
3.1.3 Avastin 21
3.1.4 Gemzar 22
3.1.5 Taxotere 23
3.1.6 Tykerb 24
3.1.7 Femara 25
3.1.8 Aromasin 25
3.1.9 Zoladex 25
3.1.10 Arimidex 26
3.2 Heat Map for Marketed Products 26

4 Breast Cancer Therapeutics in Asia-Pacific Markets to 2020 - Pipeline Analysis 28
4.1 Overall Pipeline 28
4.2 Pipeline Analysis by Molecule Type 30
4.3 Pipeline Analysis by Mechanism of Action 32
4.4 Clinical Trials - Failure Rate 34
4.5 Clinical Trial Size 35
4.6 Duration 37
4.7 Promising Drug Candidates in Pipeline 38
4.7.1 Buparlisib 38
4.7.2 Palbociclib 38
4.7.3 Afatinib dimaleate 38
4.7.4 Entinostat 39
4.7.5 Neratinib 39
4.7.6 BMN-673 40
4.7.7 Etirinotecan pegol 40

Enquire About Report at http://www.researchbeam.com/breast-cancer-therapeutics-in-asia-pacific-to-2020-novel-her-2-positive-therapies-provide-diversified-treatment-options-market/enquire-about-report

5 Breast Cancer Therapeutics in Asia-Pacific Markets to 2020 - Market Forecast to 2020 41
5.1 Asia-Pacific Market 41
5.1.1 Treatment Usage Patterns 41
5.1.2 Market Size 41
5.2 India 43
5.2.1 Treatment Usage Patterns 43
5.2.2 Annual Cost of Therapy 43
5.2.3 Market Size 43
5.3 Australia 45
5.3.1 Treatment Usage Patterns 45
5.3.2 Annual Cost of Therapy 45
5.3.3 Market Size 45
5.4 China 47
5.4.1 Treatment Usage Patterns 47
5.4.2 Annual Cost of Therapy 47
5.4.3 Market Size 47
5.5 Japan 49
5.5.1 Treatment Usage Patterns 49
5.5.2 Annual Cost of Therapy 49
5.5.3 Market Size 49

Similar Market Published Reports 

• Non-Small Cell Lung Cancer Market to 2020 - New Therapies to Enhance Treatment Segmentation and Drive Growth in an Increasingly Competitive Market - GBI Research, a leading business intelligence provider, has released its latest research report, "Non-Small Cell Lung Cancer Market to 2020 - New Therapies to Enhance Treatment Segmentation and Drive Growth in an Increasingly Competitive Market". The value of the Non-Small Cell Lung Cancer (NSCLC) market is expected to increase significantly over the forecast period across the leading eight developed nations, from $5.1 billion in 2013 to $7.9 billion in 2020. This equates to a Compound Annual Growth Rate (CAGR) of 6.6%. Growth will be driven by novel therapies entering the squamous cell carcinoma market segment, which is currently lacking effective treatment, unlike the non-squamous market segment.

View the Non-Small Cell Lung Cancer Market to 2020 Report at http://www.researchbeam.com/non-small-cell-lung-cancer-to-2020-new-therapies-to-enhance-treatment-segmentation-and-drive-growth-in-an-increasingly-competitive-market

• Ovarian Cancer Therapeutics in Major Developed Markets to 2020 - Late-Stage Pipeline Focuses on Improved Progression Free-Surival and Targeted Therapies - GBI Research, has released the pharma report -"Ovarian Cancer Therapeutics in Major Developed Markets to 2020 - Late-Stage Pipeline Focuses on Improved Progression Free-Surival and Targeted Therapies". The current Ovarian cancer therapeutics market is dominated by the use of generics - predominately carboplatin and paclitaxel, which are used in combination for the treatment of platinum-sensitive disease (both first-line and recurrent). Initial treatment with platinum-based therapy is usually effective, with approximately 70% of patients entering remission. However, even with extended progression free-survival of 24 months, almost all patients relapse, and after successive periods of remission and relapse either die or progress to platinum-resistant disease, for which the prognosis is poor. There is a clear gap in the market for maintenance therapies to extend the initial high rates of remission, and hopefully stimulate long-term remission in patients. As well as a gap for more effective treatment options in platinum-resistant or refractory patients.

View the Ovarian Cancer Therapeutics in Major Developed Markets to 2020 Report at http://www.researchbeam.com/ovarian-cancer-therapeutics-in-major-developed-to-2020-late-stage-pipeline-focuses-on-improved-progression-free-surival-and-targeted-therapies-market

• HIV Therapeutics in Major Developed Markets to 2019 - Limited Pipeline Efficacy Improvement, Patent Expirations and Stringent Healthcare Spending to Suppress Market Growth - The leading business intelligence provider GBI Research has released its latest research report, entitled, 'HIV Therapeutics in Major Developed Markets to 2019 - Limited Pipeline Efficacy Improvement, Patent Expirations and Stringent Healthcare Spending to Suppress Market Growth'. The report provides insights into the HIV (Human Immunodeficiency Virus) therapeutics market including market forecasts up to 2019. It provides an in-depth analysis of the major marketed products, as well as insights into the HIV therapeutics R&D pipeline. The report provides in-depth analysis of the unmet needs, drivers and barriers that affect the global HIV therapeutics market. The report analyzes the market for HIV therapeutics in eight major markets of the US, the top five countries in Europe (the UK, Germany, France, Italy and Spain), Japan and Canada. The report discusses the global pipeline for all the HIV molecules across various stages of development. The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research's team of industry experts. GBI Research found that the HIV therapeutics market in the top seven markets was valued at $14.3 billion in 2012 and is projected to witness growth of 1.9% during the 2012-2019 forecast period to reach $16.3 billion.

View the HIV Therapeutics in Major Developed Markets to 2019 Report at http://www.researchbeam.com/hiv-therapeutics-in-major-developed-to-2019-limited-pipeline-efficacy-improvement-patent-expirations-and-stringent-healthcare-spending-to-suppress-growth-market

• Prostate Cancer Therapeutics Market to 2019 - Rising Prevalence and Strong Uptake of Recent Approvals to Drive Robust Growth to 2019 - GBI Research has released the pharmaceutical report "Prostate Cancer Therapeutics Market to 2019 - Rising Prevalence and Strong Uptake of Recent Approvals to Drive Robust Growth to 2019". The recent approval of a number of highly effective drugs, including Zytiga and Xtandi, has provided late-stage patients with a number of options and increased survival times by a number of months. These recent approvals are anticipated to generate strong revenues during the forecast following increasing uptake by physicians as the treatment algorithm shifts towards their first-line usage over Taxotere. Additionally, a very large late-stage pipeline is anticipated to produce a number of new market entrants which are superior to existing products. Overall, this is anticipated to drive rapid market growth from $4.1 billion in 2012 to $8.0 billion by 2019 at a CAGR of 10.1%.

View the Prostate Cancer Therapeutics Market to 2019 Report at http://www.researchbeam.com/prostate-cancer-therapeutics-to-2019-rising-prevalence-and-strong-uptake-of-recent-approvals-to-drive-robust-growth-to-2019-market

Contact Us: 

Deep Joshi
5933 NE Win Sivers Drive,
#205, Portland, OR 97220
United States
Direct: +1 (617) 674-4143
Toll Free: +1 (855) 711-1555
Fax: +1 (855) 550-5975
Mail: sales@researchbeam.com
Blog: researchbeam.blogspot.com

SOURCE Research Beam